Research Focus
Andrea has expertise in integrating basic research and translational science and in drug discovery and development, spanning from preclinical to early clinical stage of development. At the University of Bern, Andrea contributed to the NCCR TransCure project aimed at combining basic research and early-stage drug discovery on endocannabinoid system modulators. He has made significant contributions to the understanding of endocannabinoid system modulators and led the clinical development of first-in-class Selective Endocannabinoid Reuptake Inhibitors (SERIs) generated in the laboratory of Prof. Jürg Gertsch. This work culminated in the founding of Synendos Therapeutics AG, advancing the first drug candidate of SERIs into clinical development.
